Document is current
Any future updates will be listed below
-
Authors
An, Lijun https://orcid.org/0000-0003-1030-4625
Pichet Binette, Alexa
Hristovska, Ines
Vilkaite, Gabriele https://orcid.org/0009-0009-6985-4307
Xiao, Yu
Zendehdel, Romina
Dong, Zijian
Smets, Bart
Saloner, Rowan https://orcid.org/0000-0002-1351-6183
Tasaki, Shinya https://orcid.org/0000-0003-3656-7394
Xu, Ying https://orcid.org/0009-0006-0387-2439
Krish, Varsha
Imam, Farhad https://orcid.org/0000-0003-2854-2568
Janelidze, Shorena https://orcid.org/0000-0003-2869-8378
van Westen, Danielle https://orcid.org/0000-0001-8649-9874
,
Stomrud, Erik
Whelan, Christopher D.
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Ossenkoppele, Rik
Mattsson-Carlgren, Niklas https://orcid.org/0000-0002-8885-7724
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
Vogel, Jacob W. https://orcid.org/0000-0001-6394-9940
- License Information
-
More Information
Article History
Received: 18 April 2025
Accepted: 23 February 2026
First Online: 31 March 2026
Competing interests
: Y. Xu is the cofounder of Andia Health. E.S. has acquired research support (for the institution) from Beckman Coulter, Bristol Myers Squibb, C2N Diagnostics, Eisai, Fujirebio, GE Healthcare and Roche Diagnostics. S.P. has acquired research support (for the institution) from Avid Radiopharmaceuticals and ki elements through ADDF. In the past 3 years, he has received consultancy/speaker fees from BioArtic, Danaher, Eisai, Eli Lilly, Novo Nordisk, Roche and Sanofi. R.O. is currently a full-time employee of Eli Lilly and Company. His contribution to the work presented in this paper was performed as an employee of Amsterdam University Medical Centers and Lund University. R.O. has received research funding/support from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer’s fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden, Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer and was an advisory board/steering committee member for Asceneuron, Biogen, Johnson & Johnson and Bristol Myers Squibb. All the aforementioned has been paid to Amsterdam University Medical Centers and Lund University. N.M.-C. has received consultancy/speaker fees from Biogen, Eli Lilly, Owkin and Merck. O.H. is an employee of Lund University and Eli Lilly. J.W.V. has received advisory fees from Manifest Technologies within the past 2 years. The other authors declare no competing interests.
